| P50 | author | Laura M. Bohn | Q40626898 |
| P2093 | author name string | Cullen L Schmid | |
| P2860 | cites work | Arrestins: ubiquitous regulators of cellular signaling pathways | Q21184142 |
| | Functional Selectivity and Classical Concepts of Quantitative Pharmacology | Q22242288 |
| | Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference | Q24294614 |
| | Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling | Q24299892 |
| | beta-Arrestin: a protein that regulates beta-adrenergic receptor function | Q24305145 |
| | A beta-arrestin 2 signaling complex mediates lithium action on behavior | Q24306355 |
| | An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior | Q24310712 |
| | Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds | Q24605173 |
| | Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo | Q24647416 |
| | Sensitivity to delta9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2 -/- mice | Q24647599 |
| | Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms | Q28181949 |
| | Transduction of receptor signals by beta-arrestins | Q28246395 |
| | A possible correlation between drug-induced hallucinations in man and a behavioural response in mice | Q28251398 |
| | A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation | Q28252768 |
| | Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family | Q28264339 |
| | G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization | Q28276743 |
| | Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior | Q28286238 |
| | Enhanced morphine analgesia in mice lacking beta-arrestin 2 | Q28504554 |
| | beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking | Q28507206 |
| | beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation | Q28512807 |
| | Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors | Q28584983 |
| | Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence | Q28590279 |
| | Beta-arrestins and cell signaling | Q29616793 |
| | Opioids: first lessons from knockout mice | Q33547877 |
| | Regulation of tyrosine kinase cascades by G-protein-coupled receptors. | Q33597362 |
| | Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor | Q33819496 |
| | Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. | Q34064133 |
| | No hypothermic response to serotonin in 5-HT7 receptor knockout mice | Q34331037 |
| | Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein) | Q34376629 |
| | beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor | Q34562493 |
| | An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization | Q34580057 |
| | Exploring the opioid system by gene knockout | Q34641459 |
| | Beta-arrestin-biased ligands at seven-transmembrane receptors | Q34654662 |
| | Activation and targeting of mitogen-activated protein kinases by G-protein-coupled receptors. | Q34677473 |
| | A universal technology for monitoring G-protein-coupled receptor activation in vitro and noninvasively in live animals. | Q34702244 |
| | Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. | Q35026544 |
| | A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine | Q35227269 |
| | Beta-arrestin-2 regulates the development of allergic asthma | Q35242857 |
| | G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice. | Q35682949 |
| | Desensitization of G protein-coupled receptors and neuronal functions | Q35817048 |
| | Novel roles for arrestins in G protein-coupled receptor biology and drug discovery | Q36256047 |
| | Morphine-activated opioid receptors elude desensitization by beta-arrestin | Q36280218 |
| | Seven-transmembrane receptor signaling through beta-arrestin | Q36305171 |
| | Beta-arrestins specifically constrain beta2-adrenergic receptor signaling and function in airway smooth muscle | Q36445260 |
| | Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness | Q36514037 |
| | Opioid receptor signaling: relevance for gastrointestinal therapy | Q36578731 |
| | The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking | Q36589457 |
| | Physiological roles of G protein-coupled receptor kinases and arrestins | Q36737680 |
| | Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. | Q36870038 |
| | Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors | Q36880900 |
| | GPCR functional selectivity has therapeutic impact | Q36880909 |
| | Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models | Q37156680 |
| | Beta-arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration | Q37383096 |
| | Characterization of G protein-coupled receptor regulation in antisense mRNA-expressing cells with reduced arrestin levels | Q38323153 |
| | Regulation of transmembrane signaling by receptor phosphorylation | Q39507854 |
| | Effects of morphine upon the lamina V type cells activities in the dorsal horn of the decerebrate cat | Q40006570 |
| | beta-arrestin-biased agonism at the beta2-adrenergic receptor | Q40034384 |
| | The V2 vasopressin receptor stimulates ERK1/2 activity independently of heterotrimeric G protein signalling | Q40253140 |
| | High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay | Q40386521 |
| | Protein kinases that phosphorylate activated G protein-coupled receptors. | Q40545369 |
| | Desensitization of G protein-coupled receptors | Q41028988 |
| | Receptor-specific desensitization with purified proteins. Kinase dependence and receptor specificity of beta-arrestin and arrestin in the beta 2-adrenergic receptor and rhodopsin systems | Q41089415 |
| | The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine | Q41099566 |
| | Pharmacology and mechanisms of opioid analgesic activity | Q41374982 |
| | Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. | Q42528174 |
| | The role of D2-like dopamine receptors in the locomotor stimulant effects of cocaine in mice | Q43618072 |
| | 5-HT(2A) receptors: location and functional analysis in intestines of wild-type and 5-HT(2A) knockout mice | Q43964308 |
| | Knockdown of spinal opioid receptors by antisense targeting beta-arrestin reduces morphine tolerance and allodynia in rat. | Q44014506 |
| | Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery | Q44345837 |
| | Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. | Q44653385 |
| | Morphine side effects in beta-arrestin 2 knockout mice | Q46510708 |
| | Modulation of voluntary ethanol consumption by beta-arrestin 2. | Q46681480 |
| | Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. | Q48244523 |
| | Discriminative stimulus properties of the serotonergic agent 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). | Q52260595 |
| | beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation | Q77452079 |
| | A cluster of differentially expressed signal transduction genes identified by microarray analysis in a rat genetic model of alcoholism | Q79841480 |
| | Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2 | Q81391001 |
| P433 | issue | 3 | |
| P921 | main subject | pharmacology | Q128406 |
| P304 | page(s) | 285-293 | |
| P577 | publication date | 2008-12-06 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Physiological and pharmacological implications of beta-arrestin regulation | |
| P478 | volume | 121 | |